A detailed history of Bray Capital Advisors transactions in Cognition Therapeutics Inc stock. As of the latest transaction made, Bray Capital Advisors holds 2,250 shares of CGTX stock, worth $1,620. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,250
Previous 2,250 -0.0%
Holding current value
$1,620
Previous $3,000 66.67%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 01, 2022

BUY
$1.5 - $3.45 $3,375 - $7,762
2,250 New
2,250 $5,000
Q1 2022

May 03, 2022

SELL
$2.41 - $6.9 $602 - $1,725
-250 Closed
0 $0
Q4 2021

Jan 31, 2022

BUY
$5.1 - $12.98 $1,275 - $3,245
250 New
250 $2,000

Others Institutions Holding CGTX

About COGNITION THERAPEUTICS INC


  • Ticker CGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 22,710,700
  • Market Cap $16.4M
  • Description
  • Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical tr...
More about CGTX
Track This Portfolio

Track Bray Capital Advisors Portfolio

Follow Bray Capital Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bray Capital Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Bray Capital Advisors with notifications on news.